FRTX Stock Overview
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Fresh Tracks Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.88 |
| 52 Week High | US$1.10 |
| 52 Week Low | US$0.45 |
| Beta | 0.49 |
| 1 Month Change | -4.51% |
| 3 Month Change | -10.20% |
| 1 Year Change | 37.49% |
| 3 Year Change | -97.67% |
| 5 Year Change | n/a |
| Change since IPO | -99.58% |
Recent News & Updates
Recent updates
Brickell Biotech changes name to Fresh Tracks Therapeutics
Sep 07Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M
Aug 11Brickell Biotech regains Nasdaq compliance for minimum bid price requirement
Jul 20Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely
Feb 14
Brickell Biotech Advances To Phase III As It Eyes Commercialization
May 10Brickell Biotech completes patient enrollment in late-stage sweat disorder study
Apr 27Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.
Jan 06
Brickell Biotech (BBI) Investor Presentation - Slideshow
Dec 02Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26
Nov 18Shareholder Returns
| FRTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.9% | -3.1% |
| 1Y | 37.5% | -1.8% | 20.9% |
Return vs Industry: FRTX exceeded the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: FRTX exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| FRTX volatility | |
|---|---|
| FRTX Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FRTX has not had significant price volatility in the past 3 months.
Volatility Over Time: FRTX's weekly volatility has decreased from 13% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 4 | Bert Marchio | www.frtx.com |
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022.
Fresh Tracks Therapeutics, Inc. Fundamentals Summary
| FRTX fundamental statistics | |
|---|---|
| Market cap | US$5.44m |
| Earnings (TTM) | -US$5.69m |
| Revenue (TTM) | US$8.01m |
0.7x
P/S Ratio-0.9x
P/E RatioIs FRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FRTX income statement (TTM) | |
|---|---|
| Revenue | US$8.01m |
| Cost of Revenue | US$3.18m |
| Gross Profit | US$4.82m |
| Other Expenses | US$10.52m |
| Earnings | -US$5.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 60.25% |
| Net Profit Margin | -71.12% |
| Debt/Equity Ratio | 0% |
How did FRTX perform over the long term?
See historical performance and comparison